Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

January 12, 2018: By Joan McKenna

Ohr Pharmaceutical announced Jan. 5 that squalamine used in combination with Lucentis failed to meet its primary efficacy endpoint in a Phase III study in patients with wet age-related macular degeneration (AMD).

The endpoint was mean visual acuity gain at nine months. Subjects receiving topically administered squalamine with monthly Lucentis injections (n=119) achieved a mean gain of 8.33 letters from baseline, while those treated with Lucentis monotherapy (n=118) achieved 10.58 letters. There were no differences in the safety profile between the two treatment groups.

Jason Slakter, MD, chief executive officer of Ohr, expressed disappointment and said, “We are grateful to the patients and physicians who participated in the clinical trial. Based on these results, we intend to evaluate strategic alternatives to maximize shareholder value.”

In February 2017, Ohr paused enrollment in the Phase III trial at 200 following the failure of other retinal combo therapies. Ohr said the move would enable it to potentially confirm the visual acuity benefits observed in the patient population it identified as the most likely to benefit from squalamine combination therapy.

Squalamine is intended to inhibit vascular endothelial growth factor, platelet-derived growth factor, and basic fibroblast growth factor. It is based on a compound found in the tissues of the dogfish shark. The FDA granted it fast track designation for wet AMD.

Ohr acquired squalamine from by Genaera Pharma in 2009 as Genaera liquidated its assets.

In April 2017, Ohr closed a $14.2 million public offering.

In December 2016, the company closed a $7.8 million public offering.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Optical Coherence Tomography Report: A Global Market Analysis for 2017 to 2023